Author Contributions: Dr Kociol had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kociol, Lopes, Clare, Mehta, Kaul, Pieper, Hochman, Weaver, Armstrong, Granger, Patel.
Acquisition of data: Patel.
Analysis and interpretation of data: Kociol, Lopes, Clare, Thomas, Mehta, Kaul, Pieper, Hochman, Weaver, Armstrong, Granger, Patel.
Drafting of the manuscript: Kociol, Lopes, Clare, Mehta, Kaul, Pieper, Hochman, Weaver, Armstrong, Granger, Patel.
Critical revision of the manuscript for important intellectual content: Kociol, Lopes, Clare, Thomas, Mehta, Kaul, Pieper, Hochman, Weaver, Armstrong, Granger, Patel.
Statistical analysis: Clare, Thomas.
Obtained funding: Granger, Patel.
Study supervision: Patel.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: This research was supported by unrestricted funding from the Duke Clinical Research Institute. Procter & Gamble Pharmaceuticals and Alexion Pharmaceuticals jointly funded the Assessment of Pexelizumab in Acute Myocardial Infarction trial. This work was supported by an award from the American Heart Association–Pharmaceutical Roundtable and David and Stevie Spina.
Role of the Sponsors: The sponsors played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Additional Contributions: We would like to thank Erin LoFrese, MS, Duke Clinical Research Institute, for her editorial contributions to this article. Ms LoFrese did not receive compensation for her contributions, apart from her employment at the institution where this study was conducted.